Navigation Links
Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
Date:4/29/2011

a laser focus on the execution of our strategy.  I am confident that with their added contributions, Savient will bring KRYSTEXXA into the hands of even more doctors, institutions and infusion centers around the globe."

  • Marsha Wolfson, M.D., has been named Vice President, Clinical Affairs & Interim Chief Medical Officer.  Dr. Wolfson will be responsible for the operations, planning and integration for all clinical activities and medical affairs relating to KRYSTEXXA. Wolfson is a board certified nephrologist with academic research and pharmaceutical industry experience in all aspects of drug development, including clinical trial design and implementation, data interpretation and communication, safety review and assessment.  She spent significant time at Baxter International, Inc., Centocor Ortho Biotech Services and Amgen and boasts in-depth expertise in global clinical development planning, interacting with regulatory agencies, and assessing and managing product quality and safety reports.  

  • Bruce Yeager has been named Vice President of Reimbursement and Managed Markets.  Mr. Yeager will lead the overall management of reimbursement programs and patient access programs to support the successful U.S. launch of KRYSTEXXA.  Yeager has 20 years of experience in sales and marketing management and joins Savient from UCB, where he was Director of Site of Care and Access Strategy.  Prior to UCB, Yeager served as a Director of Marketing at Amgen.

  • Kevin Peacock joins Savient as Senior Director and Product Champion of KRYSTEXXA.  Peacock brings with him a wealth of product marketing experience, previously serving as Senior Director of New Product Planning at Allos Therapeutics, as well as Director of Global New Products Strategic Marketing at ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company.

  • Stephen Smolinski joins Savient as Senior Director of Marketing.  Smolin
    '/>"/>

  • SOURCE Savient Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
    2. Savient Provides Update on Pegloticase BLA
    3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
    4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
    5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
    6. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
    7. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
    8. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
    9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
    10. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
    11. Savient Pharmaceuticals To Hold First Quarter 2010 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" research ... http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging of ... orthopedic instrument industry has seen rapid development ... 3.28 billion yuan in 2006 to 9.85 billion yuan ...
    (Date:1/15/2014)... 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has ... - Global Industry Analysis, Size, Share, Growth, Trends And ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... on patients in order to treat dental impairments, for ...
    (Date:1/15/2014)... WASHINGTON , Jan. 15, 2014 AARP Foundation today ... support older adults suffering from the severe cold weather that ... are committed to helping those in need; so to support ... dollar-for-dollar contributions up to $250,000, which could mean up to ...
    Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
    ... ST. LOUIS, Oct. 25, 2011 HIGHLIGHTS:2011 ... Q3 2011 reported sales increased 11% to ... products and Fine Chemicals ("SAFC") sales growing organically by 4% ... and changes in foreign currency exchange rates contributed an additional ...
    ... Company (NYSE: LLY ) has updated its full-year 2011 ... company,s Xigris ® product. Lilly expects to incur ... and contractual commitments related to Xigris. The exact amount of the ... in the range of $75.0 million to $95.0 million (pre-tax), or ...
    Cached Medicine Technology:Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 2Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 4Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 5Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 6Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 7Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 8Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 9Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 10Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 11Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 12Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 13Lilly Provides Update on 2011 Financial Guidance Due to Xigris Withdrawal 2
    (Date:7/9/2014)... may smell of flatulence and have a reputation for being ... hydrogen sulfide is now being being found to offer potential ... stroke, heart attacks and dementia. A new compound (AP39), designed ... key to future therapies, by targeting delivery of very small ... inside cells. , Scientists in Exeter have already found ...
    (Date:7/9/2014)... conducted by researchers at Tufts University School of Dental ... and developmental disabilities, the likelihood of having cavities decreased ... The findings, published in the July/August issue of ... designed to address the oral health of individuals in ... records of 107 patients at one of the eight ...
    (Date:7/9/2014)... , , , , , ... , , , , , ... binaural recording using KEMAR, the weapon was an SA80 assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... ... , , , , ... , , , , , ...
    (Date:7/9/2014)... Keck School of Medicine of the University of ... a specific component of the immune system are ... of infection. The discovery suggests that blocking this ... human autoimmune and hyper-inflammatory diseases such as rheumatoid ... was published online on June 23 in ...
    (Date:7/8/2014)... LIVERMORE, Calif. The Department of Defense,s Defense ... National Laboratory (LLNL) up to $2.5 million to ... to record and stimulate neurons within the brain ... week. , The research builds on the understanding ... in certain regions of the brain encode information, ...
    Breaking Medicine News(10 mins):Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3
    ... unawares, leading to heart failure and even death. This ... valve// or arterial diseases and congenital heart defects, but ... in the bloodstream. ,In a paper to ... Nature Structural and Molecular Biology, a Rutgers-Newark researcher and ...
    ... first group of Electronic Health Record (EHR) products ... Records// Vendors Association (EHRVA) recognizes this achievement and ... accelerate EHR adoption. ,“EHRVA works to ... the significant value they provide to patients, providers, ...
    ... Researchers from Florida Atlantic University, the Center for Breast ... Hospital, and MeVis, The Center for Diagnostic// Systems and ... new techniques to aid clinicians in the diagnosis and ... developed and piloted a unique software platform utilizing computational ...
    ... in Australia to the grant of patent application to ... discovery of RNAi has been withdrawn.// This was announced ... of Massachusetts Medical School. The opposition was originally filed ... Announcement of the withdrawal will be published in Australia's ...
    ... insufficient oxygen supply to the heart as the critical ... a hypothermic state.// ,Writing in the July ... Physiology, researchers found no significant difference in the amount ... to one hour of severe hypothermia and rats exposed ...
    ... Pradesh government to stop functioning of all but one medical ... ,The court asked the state government not to ... ,The order was passed by Justice Sunil Ambawani on a ... ban on quacks in the state., ,However, the court ...
    Cached Medicine News:Health News:Heart disease and strokes connected to a motor protein mechanism 2Health News:EHRVA Supports EHR Product Certification 2Health News:New Tool to Diagnose and Treat Breast Cancer 2Health News:New Tool to Diagnose and Treat Breast Cancer 3Health News:Heart Has Enough Oxygen to Survive Hypothermia; CPR Crucial 2Health News:Heart Has Enough Oxygen to Survive Hypothermia; CPR Crucial 3
    Suture Cutter, 15 Up Curve...
    Portal accessory instrument set. Set also includes a package of 8 mm Guide Wires (.15 cm x 38 cm), and Sterilization Tray....
    ...
    Knot tier...
    Medicine Products: